Dundee biotech wins $2.7m Gates Foundation grant for disease-drug research

Business · First reported 9 Nov, 08:14 · Updated 08:25

Image: Wikimedia Commons · NASA Earth Observatory image by Lauren Dauphin, using Landsat data from the U.S. Geological Survey. Story by Adam Voiland. · Public domain

PhaSER Biomedical has secured a two-year $2.7 million (£2 million) Gates Foundation grant to support research into drugs for diseases including tuberculosis and malaria. The award renews the company’s participation in a programme that provides teams with shared laboratory tools and access to PhaSER’s humanised mouse model.

PhaSER Biomedical received a two-year $2.7 million (£2 million) Gates Foundation grant to help find drugs for diseases including tuberculosis and malaria.
The grant renews PhaSER’s place in the Gates Foundation’s Global Health Discovery Collaboratory, where researchers can use the company’s 8HUM mouse model and expertise in drug metabolism.
PhaSER is also developing HERALD, an AI tool intended to predict harmful side effects from combinations of medicines, with the University of Dundee and the MHRA.

Summary written by Lux AI from 2 articles

Key facts

Grant: $2.7 million (£2 million), for two years.
Awarding organisation: Gates Foundation.
Research model: PhaSER’s 8HUM mouse carries human versions of key genes involved in breaking down drugs.
Previous grant: PhaSER announced a $2.3 million Gates grant in 2024.
HERALD funding: The MHRA said in October 2025 that the project would receive £859,650 in government funding.